Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin/Singulair combo stumbles

Executive Summary

Phase III trials of a combination of the antihistamine Claritin and the asthma agent Singulair "did not demonstrate a statistically significant improvement in the treatment of seasonal allergic rhinitis compared to each product administered separately," Schering-Plough and Merck say. The firms will continue to evaluate the results and may conduct additional studies. The combo is under development via a joint venture formed in 2000 (1"The Pink Sheet" May 29, 2000, p. 22). Merck is conducting Phase III trials of Singulair monotherapy for allergic rhinitis...

You may also be interested in...

Singulair Advantage In Allergies Is Leukotriene-Blocking Action, Merck Says

Merck's Singulair AR novel mechanism of action allows the asthma drug to work across multiple allergic rhinitis symptoms, Human Health President-Americas David Anstice told investors

Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms

Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.

Academia Meets The Market – Part Two

New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts